Ultrasound: A Chemotherapy Sensitizer
Introduction
Chemotherapy plays a very important role in cancer treatment. Chemotherapy alone can cure trophoblastic malignancies; thus, under these circumstances chemotherapy is the first choice (1). Antineoplastic chemicals can also be used as adjuvant therapy, and their use after surgery has been clinically adopted. Furthermore, several novel modalities such as neoadjuvant chemotherapy, chemoradiation, and chemoembolization, have been developed in recent years (2-5).
Chemotherapy-related toxicities are a serious problem; they reduce the quality of life, even interrupt a treatment plan. Oncologists hope to develop techniques, by which the therapeutic effects could be maintained while reducing side effects as far as possible. The development of chemoresistance is the other obstacle that needs to be overcome in achieving successful chemotherapy. Theoretically, selecting agents individually based upon an in vitro chemotherapy sensitivity assay can spare the use of ineffective agents, thus lowering the development of refractory diseases (6). However, this is not recommended by the American Society of Clinical Oncology (ASCO) as there are no sufficient supportive evidences (7) . For chemoresistant cases, malignant cells can be killed only after overcoming chemotherapy resistance. The mechanisms of chemoresistance are so complex that it is difficult to develop chemosensitizers (8) . The present available chemoresistance modifiers cannot be adopted clinically as a result of severe toxicological adverse effects, although they work well in vitro. Researchers hope to balance pharmacodynamical and toxicological effects by restructuring the molecules. Developing non-drug modalities is the other solution.
Ultrasound has been used to detect lesions for decades. Now, there is a deeper understanding of the biological effects induced by ultrasound in tissues; consequently, ultrasonic therapy has been developed. Ultrasound exposure results in structural and functional changes in tissues; the use of ultrasound can directly kill cells or modulate cellular physiological/pathophysiological functions. Therefore, ultrasound can be concurrently used with other stimuli to reach therapeutic goals (9).
The use of ultrasound to synergize anticancer chemicals has been considered for many years. In 1976, Kremkau et al. reported that ultrasound enhanced the cytotoxicity of nitrogen mustard to mouse leukemia (10). However, ultrasound-assisted chemotherapy has not been investigated systemically until 1990s. This technique is based upon the finding that ultrasound exposure improves membrane permeability thus enhancing the trans-membrane influx of chemicals. The increase of intracellular drug accumulation enhances cell killing.
The main focus of this article is on the use of ultrasound in enhancing chemotherapy. Anticancer drugs, which can be enhanced by insonation either in vitro or in vivo, will be reviewed. Ultrasound exposure can be used to release drugs within a specific volume, suggesting it as a potential technique for targeted chemotherapy. High energy shock waves (HESW) employed in lithotripsy, which are characterised by high amplitudes, high pressures, low pulse durations, and low pulse repetition rates, result in distinct bioeffects, although they are classed as ultrasound waves (11). Therefore, they are not within the scope of this chapter.
Enhancing Chemotherapy
Oncologists hope to achieve the therapeutic effects of chemotherapy by using a lowered dosage, i.e., sensitizing chemotherapy. Experimental investigations show that ultrasound is a chemotherapy sensitizer. Some agents have been adopted in ultrasonic chemotherapy.
Adriamycin (ADR)
Saad and Hahn investigated the effect of ultrasound (2.025 MHz, exposure duration of 30 min) on the cytotoxicity of ADR to Chinese hamster ovary cell line HA1. The synergism occurred at an intensity of 0.5 W/cm 2 and a temperature of 41 ºC; cell killing was significantly enhanced even at 37 ºC when intensity was increased to 1 W/cm 2 (12). The combination of ADR and ultrasound (2.6 MHz, 2.3 W/cm 2 , continuous wave) resulted in lower clone survival rates in Chinese hamster lung fibroblast cells V79-379A, compared with those attributable to ADR alone (13). In the experiment performed by Harrison et al., continuous wave ultrasound (1.765 MHz, 1.0 W/cm 2 ), tone burst ultrasound (1.765 MHz, 0.25 W/cm 2 , 10% duty cycle), and pulsed ultrasound (2.5 MHz central frequency, 1 kHz repetition frequency, 0.18 W/cm 2 ) enhanced ADR-induced cell killing in CHO cells; continuous wave ultrasound and tone burst ultrasound induced a 25-fold potentiation at 2.5 μg/ml ADR. Tone-burst ultrasound-mediated synergism also occurred in human breast carcinoma cells MCF-7WT. However, there were negative findings in V79 cells (14) . In vitro potentiation was also confirmed in 3AO human ovarian carcinoma cells (0.24 MHz, 5.12 W/cm 2 ) and HL-60 leukemia cells (80 kHz) (15, 16) . Employing ultrasound either before or after ADR administration led to the potentiation; however, administrating ADR prior to insonation resulted in a lower clone-surviving rate (16).
4'-O-tetrahydropyranyladriamycin (THP), a derivative of ADR, did not kill Sarcoma 180 cells in vitro at a concentration of 80 μM. But the combination of THP and 60 s ultrasound exposure (1.93 MHz, 3 W/cm 2 ) resulted in a 2-times-higher cell death rate compared with insonation alone (17). Based on this finding, two conclusions can be drawn. One is that THP enhances ultrasound and the other is that ultrasound sensitizes THP. As THP is a cytotoxic agent, we believe that ultrasound is the sensitizer. An antineoplastic agent can be used to distinguish ultrasound-assisted chemotherapy (ultrasonic chemotherapy) from sonodynamic therapy (SDT). The modality is ultrasound-assisted chemotherapy, where anticancer drugs are concurrently administrated with insonation, i.e., the use of ultrasound enhances drug-induced cell killing. However, if the agents are not normally adopted for chemotherapy, such as porphyrins and anti-inflammatory agents, the technique is SDT where ultrasound plays the leading role (9, 18) .
Ultrasound also potentates chemotherapy in vivo. Harrison et al. reported that tone-burst ultrasound (1.765 MHz, 0.25 W/cm 2 , 10% duty cycle) and pulsed ultrasound (2.5 MHz central frequency, 1 kHz repetition frequency, 0.18 W/cm 2 ) synergized ADR, when it was used to treat uterine cervical tumors implanted in hamster cheek pouches. The combined therapy resulted in a larger necrosis volume occurring in cancer tissues and a more significant growth delay (14). Ultrasound also enhanced the effects of ADR on fibrosarcomas RIF-1 (1.733 MHz, 0.5 W/cm 2 or 2.0 W/cm 2 ), melanomas B-16 (1.733 MHz, 2.0 W/cm 2 ), and ovarian carcinomas SKOV 3 (0.24 MHz, 7.84 W/cm 2 ) (19, 20) . The combined therapy resulted in a more significant delayed tumor growth, a smaller tumor volume and the formation of necrosis. In these trials, ADR was administrated before ultrasound irradiation.
Cisplatin (DDP)
An early investigation by Saad and Hahn suggested that there was no synergism between DDP and ultrasound (12). Harrison et al. also reported that tone-burst ultrasound with a frequency of 1.62 MHz and an acoustic pressure of 0.31 MPa did not potentiate the clonogenic cytotoxicity of DDP to CHO cells in vitro (21). In the experiment performed by Takada et al., ultrasound with a frequency of 28 kHz augmented the cytotoxicity of DDP to HeLa cells while acoustic pressure was 28 kPa, 33 kPa, or 42 kPa (22). The reason for this disagreement remained unclear.
5-Fluorouracil (5-FU)
Ultrasound (18.35 W/cm 2 ) with a frequency of 25 kHz improved therapeutic effects of 5-FU on mouse ascites tumors resulting in prolonged survival (23). The combination of 5-FU and ultrasound significantly delayed tumor growth in vivo. Mice bearing tumors were subjected to 5-FU with a dose of 10 mg/kg on days 1, 3, 5, 8, 10, and 12, with and without ultrasound. A series of ultrasound irradiation was adopted (0.8 MHz, intensities of 1, 2, and 3 W/cm 2 , exposure durations of 1, 3, and 5 min, wave forms of continuation, and pulse). There was a significant synergism between continuous wave ultrasound and 5-FU in that the combined treatment led to a 5-day longer survival. Pulsed wave ultrasound (pulse-repetition rate 1000 Hz, duty ratio 1:3) also enhanced 5-FU but the synergism was lower. The potentiation increased with increasing acoustic intensity. Ultrastructural examinations detected cytoplasmic vacuolation in tumors exposed to ultrasound, while cytoplasmic vacuolation, necrosis, and pyknosis were observed when tumors were treated with the combination of 5-FU and ultrasound irradiation (24).
Cytosine Arabinoside (Ara C)
The addition of ultrasound (48 kHz, 0.3 W/cm 2 , 60 s or 120 s exposure duration), which had no cytotoxicity, significantly suppressed clone formation in HL-60 cells attributable to Ara C with concentrations of 2×10 -9 to 1×10 -7 M. A scanning electron microscopy examination revealed that ultrasound resulted in a decrease of projected membranous microvilli, and slightly disruptive and relatively smooth cell surface (25).
Mitomycin C (MMC)
There are disagreements about the interaction between MMC and ultrasound exposure. Takada et al. reported that ultrasound potentiated the effects of MMC to HeLa cells in vitro (22). However, Harrison et al. did not demonstrate that the use of ultrasound enhanced cell deactivation due to MMC (21).
Diaziquone (AZQ)
Thirty-minute tone-burst ultrasound exposure (1.62 MHz, 0.31 MPa) enhanced AZQ-induced clone suppression in CHO cells in vitro (21) . An in vivo investigation by Harrsion et al., uterine cervical squamous carcinomas were established in hamsters by cheek pouch transplantation and AZQ was administrated intraperitoneally 5 min before exposure to tone burst ultrasound (1.765 MHz, 0.25 W/cm 2 , 10% duty cycle). Tumors did not respond to either ultrasound or drug. However, the combination of ultrasound and AZQ resulted in smaller tumor volumes (14).
Nitrogen Mustard
Leukemia cells 1210 were treated with nitrogen mustard or the combination of nitrogen mustard and continuous wave ultrasound (2 MHz, 10 W/cm 2 , 10 min), cells were then injected into the peritoneal cavity. Mice that received cells exposed to the combined therapy had a prolonged survival time compared with those animals that received cells only treated with nitrogen mustard. Some mice were "cured," which were inoculated with cells treated with both drug and insonation (10). These findings suggested that the low carcinogenicity of nitrogen mustard was augmented by the addition of ultrasound exposure.
Bleomycin (BLM)
Mouse lymphomas RL were subjected to BLM (2.5 mg/kg) and ultrasound (1 MHz, 2 W/cm 2 , 5min). BLM alone did not suppress tumors but the addition of ultrasound exposure led to cancer regression. Electric pulses (5 Hz, 100 V/cm, 8 square waves/100μs) could also enhance the anti-tumor effects of BLM. However, while both ultrasound and electric pulse were administrated after injecting BLM, the therapeutic effect was not improved compared with that due to the combinations of BLM and ultrasound, or BLM and electric pulse (26).
Cyclophosphamide (CTX)
Ultrasound exposure (2.25 MHz, 1.7 W/cm 2 ) resulted in a temperature of 44.2 ºC. The combination of CTX and 20 min-duration ultrasonic hyperthermia resulted in a more prolonged tumor volume-doubling time in implanted TCT-4909 bladder tumors compared with CTX. The maximal synergism occurred when ultrasound was applied 30 min before drug administration (27). In another in vivo trial, 30min local hyperthermia of 43±0.5 ºC caused by ultrasound (670kHz, 5 W/cm 2 ) with a suboptimal dose of CTX did not produce the synergistic effect in transplanted MX-1 breast and LX-1 lung cancers in mice (28).
Dihydroxy (oxybiguanido) boron (III) hydrochloride monohydrate (HB) and hydroxy salicylhydroxamato boron (III) (SHB)
Ehrlich ascites carcinomas were treated with HB or HB combined with ultrasound (25 kHz, 18.35 W/cm 2 ). The survival rates were prolonged significantly while ultrasound exposure was administrated after injecting HB with a dosage of 50, 200, or 300 mg/kg, compared with those caused by HB alone (23). The combined treatment resulted in a slower tumor growth rate and less viable cells. However, if insonation was given before drug administration, no synergism was detected. Ultrasound with a frequency of 25 kHz also enhanced the effect of SHB, a boron compound, against Ehrlich ascites carcinomas (29).
Thiotepa
Ultrasound (2.025 MHz, 1 W/cm 2 ) induced hyperthermia (44.2 ºC, 20 min) enhanced the effects of thiotepa in TCT-4909 bladder tumors. The potentiation occurred when ultrasound was employed 30 min before injecting thiotepa, or 15 min after drug administration. A radiolabeled drug injected after insonation showed the decreased uptakes of label up to 20 hours after heating. This finding suggested that ultrasound-induced potentiation was not mediated via an increasing drug uptake (27).
Amphotericin B (AMB)
AMB could overcome cisplatin resistance (30). Saad and Hahn reported that ultrasound (2.025 MHz, 1 W/cm 2 ) enhanced AMB-induced HA1 cell death was observed only when the exposure duration was longer than 30 min and the temperature was 43 ºC (12). Because the synergism occurred only under such narrow conditions, its application is limited.
Others
Ultrasonic (670 kHz, 5 W/cm 2 ) hyperthermia (43±0.5 ºC) synergized the effects of melphalan in transplanted MX-1 breast tumors for 30 minutes. This combination treatment resulted in tumor regression. The synergism also occurred while procarbazine was used to treat LX-1 lung cancers (28).
Overcoming Chemoresistance
Chemoresistance leads to the failure of therapy. However, the mechanisms of chemotherapy resistance are not understood thoroughly. The overlapping of mechanisms occurs frequently, thus making it difficult to design/develop chemoresistance modifiers. The potential sensitizers include calcium channel blockers, cyclosporins, hormone antagonists, protein synthesis inhibitors, and enzyme inhibitors; signal transduction modulators and gene strategies have also been developed recently (8, 31) . Clinical outcomes of these techniques have disappointed oncologists as a result of (i) unacceptable toxicity, (ii) lack of sensitization in vivo, and (iii) very limited conditions required for sensization to occur. A systematic review of the potential approaches is beyond the scope of this article. Therefore, we only introduce the utilization of ultrasound as a non-drug approach in treating refractory cancers.
Ultrasound can potentiate the effect of ADR to ADR-resistant human ovarian carcinoma cells in vitro. The addition of ultrasound (0.24 MHz, 5.76 W/cm 2 ) exposure after ADR administration led to a lower surviving rate in SKOV 3 /ADR cells although insonation alone did not kill cells (32). Ultrasound (69 kHz, 3.2 W/cm 2 ) also enhanced cell killing due to ADR micelles in multidrug resistance (MDR) ovarian cancer cells A2780/ADR (33, 34) . Encapsulated ADR had a lower risk of inducing chomoresistance and could be used in the second line treatment for ovarian cancers (35). Therefore, the interaction of ultrasound and bound ADR needs to be investigated further.
Verapamil, a calcium channel blocker, can overcome chemoreistance efficiently in vitro. However, the plasma drug concentration needed to completely sensitize chemotherapy is not feasible as a result of cardiovascular toxicities. Human can tolerate a plasma drug concentration of up to 1 μg/ml, but such a level can only partly overcome chemotherapy resistance (36, 37) . If chemoresistant human ovarian carcinoma cells were pretreated with 1 μg/ml verapamil for 24 hours, and then exposed to ADR prior to non-cytotoxic ultrasound exposure (0.24 MHz, 5.76 W/cm 2 ), survival rates would be lower than those due to the combination of ADR and verapamil (32). This finding suggested that ultrasound potentiated the chemosensitization due to verapamil. In the experiment performed by Liu et al., ultrasound (1 MHz, 0 .4 W/cm 2 ) induced hyperthermia (41 ºC) and PSC 833, an analog of cyclosporin D, were used to enhance the cytotoxicity of ADR to MDR cells MV 522/Q6 and KB-V-1. Cells were first exposed to 1-hour ADR and 20-min insonation, then 72-hour PSC 833 after washing away ADR. Either ultrasound or PSC 833 enhanced cell killing that is due to ADR treatment, and the combination of ultrasound and PSC 833 killed more cells (38). This showed that there was an additive sensitizing effect between ultrasonic hyperthermia and PSC 833. These findings suggested that the refractory diseases could be treated using the co-administration of anticancer agents, chemotherapy sensitizers, and ultrasound exposure.
Ultrasound can circumvent ADR-resistance in vivo. ADR-resistant tumors were established in mice by subrenal capsular cell fibrin clot transplantation. Both ADR and verapamil were administrated intraperetonially. Ultrasound was employed after injecting the drug. The combination of ADR (8 μg/kg) and ultrasound (0.24 MHz, 7.84 W/cm 2 ) significantly suppressed tumors compared with ADR alone. However, verapamil did not sensitize ADR and there was no synergism between verapamil and ultrasound (20). The short therapeutic duration of the treatment might have been the reason. Modifying the treatment plan and ultrasound exposure could yield a better result.
Targeted Chemotherapy
The standard chemotherapy is administered by systemically and non-selective killing of cells is the major limitation of this therapy. Targeted chemotherapy means that anticancer drugs are released within the lesions directly, thus malignant cells are destroyed efficiently and toxicity is decreased as well. Targeted chemotherapy is a very promising technique and some modalities are under development.
Ultrasound waves can be focused on a specific volume. When the ultrasonic energy deposit within the focus is high enough immediate cell killing occurs. This technique is high intensity focused ultrasound (HIFU), which has been clinically introduced to ablate solid tumors (39). Theoretically, ultrasonic energy can be adjusted to a level to release anticancer drugs within a specific region.
A microencapsulated drug has been designed for targeted chemotherapy because this form of preparation is stable in blood circulation. One can induce the collapse of micelles only when they reach the lesion. Micellar adriamycin pluronic copolymer P-105 was used to destroy HL-60 cells in vitro. IC 50 was decreased to 0.19 μg/ml while P-105 was combined with 80 kHz-sonication, whereas IC 50 due to P-105 alone was 1.25 μg/ml. An interesting phenomenon was that P-105 did not increase intracellular adriamycin content. However, ultrasound exposure significantly increased the release of adriamycin from micelles, thus resulting in a higher intracellular accumulation (15).
The structures of micelle and of packaged chemical influence the release of drugs and the uptake by cells. Adriamycin uptake in HL-60 attributable to P-105 unimers was higher than that due to polymers, and that resulting from polymers was significantly increased by 70 kHz ultrasound (40). Ultrasound (70 kHz) exposure also increased the uptake of ruboxyl, a paramagnetic analog of adriamycin (40). A wide range of acoustic frequency could enhance the release and the uptake of drugs (33, (40) (41) (42) .
In vivo investigation confirmed the efficiency of micelleultrasound chemotherapy. Transplanted rat colon tumors were treated with encapsulated ADR alone or combined with ultrasound. The combination of drug and ultrasound resulted in a smaller tumor size and a longer survival time (33, 43). The effects of micelle-ADR-ultrasound were also manifested in A2780 ovarian cancers (44). These finding showed that micellized chemicals combined with ultrasound was a hopeful technique for targeted chemotherapy. Designing micelles specifically for use with insonation could maximize the therapeutic effects.
Microbubbles are very useful tools in ultrasonography. They improve ultrasonic images, thus benefiting the detection of the lesions. Therapeutic use of microbubbles is under investigation. Administration of microbubbles accelerated thrombolysis due to insonation or to the combination of a thrombo-lytic agent and ultrasound (45) (46) (47) . This technique can also be adopted to induce the targeted release of anticancer drugs. There are two potential approaches: (i) Antitumor chemicals are incorporated into microbubble. When these microbubbles reach the lesion via circulation, ultrasound is employed to induce the collapse. Thus, drugs are released into the cancer tissues efficiently. (ii) The co-administration of micelles containing drugs and microbubbles. Ultrasound produces not only the release of drugs from micelles, it also enhances the uptake of drugs by the cancer cells. Therefore, this technique results in a higher local level of chemotherapeutic agents.
In order to improve the precision of therapy, an antibody is introduced. Cancer cell-specific antibodies are conjugated with sonosensitizers. During SDT, these conjugated agents bind efficiently with the cancer cells expressing the specific antigen. This technique significantly increased tumor suppression (48) . This strategy could also be used for microbubble-ultrasound-mediated targeted chemotherapy and the above-mentioned two approaches can benefit from this technique (Fig. 1) . The major limitation is that most available antibodies are obtained from mouse; this will induce immune reactions in humans, thus interfering with the conjugation of antibody to cells. The development of humanized antibodies is perhaps the solution. Prodrugs are not cytotoxic in blood circulation. They remain inactive until catalyzed by specific intracellular enzymes. The active forms thus generated by the enzymatic action exert the therapeutic effects (49). Prodrugs have potential for targeted chemotherapy. As ultrasound can assist in the release and the uptake of drugs, it can also be used to facilitate the influx of prodrugs. Genes encoding a specific enzyme are introduced into cells. These enzymes convert prodrugs into cytotoxic species thus killing cancer cells directly (50). This technique is another strategy for target chemotherapy. Therefore, the expression of the gene must be limited to a definite area and this can be achieved by ultrasound irradiation (51). The gene encoding the enzyme is inserted into the downstream of a promoter, which is sensitive to a temperature rise, such as a heat shock protein (HSP) promoter. Focused ultrasound is used to induce a temperature rise in tissues within the focal volume, thus producing enzymes and making prodrugs activated only in insonated cells (Fig. 2) . This technique will improve the therapeutic efficiency.
Blood brain barrier (BBB) and blood testis barrier (BTB) prevent chemotherapeutic agents from penetrating into parenchyma, thus making tumors located in these organs "chemoresistance islands." Opening these barriers will improve drug delivery, thus killing malignant cells. Ultrasound has the potential of opening BBB and this effect is enhanced by the introduction of microbubbles (52, 53). Therefore, ultrasound can be used for chemotherapy of brain cancers.
Mechanisms
The bioeffects of ultrasound result from heat and nonthermal effects (mechanical effect and cavitation) (54, 55). However, these three factors do not always function in the same way. A lower frequency benefits the onset of cavitation and a higher one favors heat production. A specific change in tissues is mostly due to a special mechanism, although all of them are involved in the process. Both ultrasound (intensity, frequency, waveform, exposure duration, focal depth in tissue, and exposure methodology) and the tissue (tissue type and physiological status) determine the effects that occur. The identical ultrasound irradiation may lead to drastically variable effects in different tissues. Following mechanisms may contribute to ultrasound-induced chemosensitization:
Increasing Intracellular Drug Content
Sonication facilitates an influx of molecules, thus improving the intracellular drug accumulation. This effect occurs in both chemosensitive and chemoresistant cells (16, 32, 33, 42, 44, 56) . Ultrasound further augments the increase of intracellular ADR accumulation in chemoresistant cells caused by verapamil (32). Insonation increases the intracellular ADR level in MDR cells and PSC 833 slows down the efflux; both of them led a prolonged retention (38). Investigators believe that it is the increased intracellular drug level that results in ultrasound-induced chemosensitization.
Hyperthermia can facilitate a drug influx, thus enhancing chemotherapy (57). Ultrasound can produce heat, and this has been used for thermochemotherapy. However, there is no temperature rise detected in most investigations (9). Furthermore, low-frequency ultrasound is also effective for chemotherapy sensitization, but this kind of ultrasound wave does not favor heat production. Even in those investigations where heat was regarded as the mechanism, the potentiation due to so-called ultrasound-induced hyperthermia was higher than that caused by an identical temperature rise (10, 19, 58) . Therefore, some nonthermal mechanisms must contribute to the observed ultrasonic chemosensitization. Ultrasound promotes membrane permeability, thus increasing intracellular drug accumulation and this permeabilization is mediated by cavitation (59). Free radicals generated by acoustic cavitation damage cell membrane and antioxidants and free radical scavengers protect cells against ultrasound-induced damages (9). The observation that the co-administration of hyperthermia and ultrasound exposure does not result in a stronger sensitization demonstrates that heat is not the only mechanism for ultrasound-assisted chemotherapy (58). ADR has a positive effect on hydroxyl radical production caused by ultrasound (60). This can explain why the synergism between ADR and ultrasound irradiation has been observed in most investigations.
Ultrasound-potentiated ADR was achieved via increasing cell membrane permeability. This made investigators believe that the cytotoxicity of only those drugs whose mode of action involved plasma membrane could be enhanced by ultrasound (12). According to this hypothesis, DDP, which functions via intercalating DNA, cannot be used for ultrasonic chemotherapy. However, Takada et al. showed that the cytotoxicity of DDP could be enhanced by ultrasound (22) . In our experiment, we determined the intracellular DDP level in human ovarian carcinoma cells using high performance liquid chromatography. The addition of insonation after administrating DDP resulted in a higher intracellular content of the drug (Fig. 3) .
MDR modulators usually take effect via inhibiting P-glycoprotein activity or suppressing the expression of mdr1. Data from a reverse transcription-polymerase chain reaction did not support the idea that ultrasound downregulated the expression of mdr1 (61). Further investigation is required to determine whether ultrasound inactivates P-glycoprotein activity.
Enhancing Apoptosis
The underlying mechanism of many cancer therapies is the induction of apoptosis. The malfunction in triggering apoptosis and/or insufficient apoptosis contributes to the failure of treatments. In human ovarian cells, apoptosis index as well as effectiveness of adriamycin therapy was improved by ultrasound suggesting that ultrasound can be used as a tool for chemotherapy (61).
The pathway of ultrasound-potentiated apoptosis remains unclear although the increase of intracellular drug content plays a role. Ultrasound exposure alone can induce apoptosis; some investigators believe that ultrasound-induced apoptosis is mediated via mitochondria-caspase pathway (62).
The pathway of cell suicide should be explored when using ultrasound as a chemotherapy sensitizer.
Sensitizing Cells
Ultrasound exposure after administering anticancer agents led to an increase in intracellular drug accumulation. However, if insonation was performed prior to adding drugs, the potentiation also occurred without the increase of intracellular drug accumulation (16). These suggested that facilitating trans-membrane drug transportation was not the only mechanism. Sheep red blood cells were put into a hypotonic solution after exposure to ultrasound, which did not lead to cell ruptures. The fraction of hemolysis was higher in exposed cells (Fig. 4) . Therefore, ultrasound exposure lowered the threshold of membrane rupture. Normal cells could tolerate a concentration of 0.69%, but membrane rupture occurred in sonicated cells under such a concentration.
The clone surviving curves of human ovarian carcinoma cells were evaluated using the "target" models in radiation biology. Single-hit, single-target model (S=Exp(-D/D 0 )) and single-hit, multi-target model (S=1-(1-Exp(-D/D 0 ) N )) were adopted, where S was the survival rate and D was the dosage. D 0 and N were cell-specifically intrinsic parameters, which determined a cell's sensitivity to stimuli. Both D 0 and N were altered whether ultrasound exposure was used before or after ADR administration (63). This could explain the potentiation despite a constant intracellular drug level. We believe that ultrasound has the potential of sensitizing cells, resulting in a lowered threshold for cell destruction.
Some cancer therapies are not mediated via induction of apoptosis and some chemotherapeutic agents can kill cells via both necrosis and apoptosis pathways (64, 65). Apoptosis indexes and survival rates due to ADR and due to a combination of ADR and ultrasound were evaluated. Survival was significantly decreased, but apoptosis rate was not increased Figure 3 : Intracellular cisplatin content determined by high performance liquid chromatography. DDP, cells were exposed to cisplatin alone; DDP+US, cells were exposed to the combination of cisplatin and ultrasound. Cisplatin was administrated prior to ultrasound irradiation.
Figure 4:
Scheme of osmotic fragility of sheep red blood cells. Hyposmosis ruptured cells, thus releasing hemoglobins; the higher an absorptance was, the higher a fraction of hemolysis was. Exposure: insonated cells. Ultrasound exposure alone did not rupture the cell membrane. proportionally. We assumed that the discrepancy resulted from the occurrence of oncosis (61). Ultrasound exposure lowered the threshold of oncosis, thus some cells were directly killed. Those cells were normally killed via apoptosis pathway if exposed to anticancer drug alone.
Accelerating the Release from Micelles
When micelles/microbubbles containing drugs are used for ultrasonic chemotherapy, ultrasound increases the release of anticancer agents. The rate of release depends on the structure of micelles, ultrasonic intensity and frequency (66). Generally speaking, the release increases with increasing intensity and a higher frequency results in a lower release rate (33, 42, 66) . Ultrasound also assists in drug release from stabilized micelles (67).
The presence of microbubbles benefits the occurrence of cavitation (9). If cavitation bubbles are used during ultrasonic chemotherapy. Sheer force resulting from the collapse of bubbles ruptures micelles/microbubbles containing anticancer chemicals. On the other hand, massive free radicals attributable to cavitation permeabilize cell membrane. These lead not only to acceleration of the release but also the transmembrane delivery of the anticancer drugs.
Summary
Investigations have demonstrated that ultrasound can be used to potentiate anticancer drugs and to circumvent chemoresistance. Ultrasound also has the potential of enhancing chemosensitization of chemoresistance modulators. Therefore, the co-administration of anticancer agents, chemotherapy sensitizers, and ultrasound exposure can efficiently treat the refractory diseases. Ultrasound-enhanced chemotherapy suggests that the therapeutic effects can be obtained with a lower dosage. Therefore, this modality will reduce the toxicities.
Ultrasound can be used to release antitumor chemicals within a definite volume, thus resulting in a higher local level in the malignant cells. This will directly and efficiently kill cancer cells. This is targeted chemotherapy. However, there is considerable disagreement in the literature regarding the effectiveness of ultrasound in targeted chemotherapy. This is because the response to ultrasound is cell-type specific. Therefore, it is important to determine which cancer type will respond to this modality. Additionally, the mode of insonation is also critical. This indicates that ultrasound exposure should be optimized for each individual patient.
Despite the progress in using ultrasound as a chemotherapy sensitizer, the mechanisms are only partly understood and needs to be further investigated.
However, ultrasonic chemotherapy has not been used for clinical cancer therapy despite these stirring findings. Following factors are perhaps the reasons. (i) The behaviors of ultrasound waves in tissues cannot be predicted as therapeutic ultrasounds operate in the rage of nonlinear acoustics. (ii) Ultrasound exposure must be specifically tailored for a specific tissue, as the response to ultrasound is tissue-specific. (iii) Only relative lower intensities can be used for ultrasonic chemotherapy but this kind of ultrasound device for clinical therapy has not been developed so far (9, 68). We believe that ultrasonic chemotherapy will change the clinical practice with the advancement of transducer design technology, the development of biological ultrasonics and the exploration of effects induced in tissues.
